MetaCap

Acrivon Therapeutics (ACRV) vs Clene (CLNN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Acrivon Therapeutics (ACRV) has outperformed Clene (CLNN) over the past year, losing 50.0% versus a loss of 62.0%. Clene is the larger company by market cap ($50.7 million vs $49.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACRV-50.00%CLNN-62.03%
+36%-18%-71%
Nov 21, 20251 yearNov 20, 2026
ACRV-92.71%CLNN-82.40%
+67%-17%-101%
Nov 14, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACRV versus CLNN key metrics
MetricACRVCLNN
Share price$1.15$3.52
Market cap$49.35M$50.69M
1-day change-17.86%+0.57%
YTD return-52.28%-40.03%
1-year return-50.00%-62.03%
5-year return—-96.28%
EPS (TTM)$-1.82$-2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$200.00K
Revenue growth (YoY)—-41.52%
Net income (latest FY)$-77.91M$-26.17M
Gross margin—78.50%
Operating margin—-11541.50%
Net margin—-13086.50%
52-week high$3.56$10.84
52-week low$0.9709$3.02
Distance from 52-week high-67.70%-67.53%
Analyst consensusnonenone
Avg. price target upside+900.00%+814.77%
Average volume275.69K115.06K
Shares outstanding42.91M14.40M
Employees7476
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ACRV has outperformed CLNN by 12.0 percentage points over the past year.

About Acrivon Therapeutics

ACRV stock →

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees

About Clene

CLNN stock →

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

ACRV vs CLNN FAQ

Which is bigger, Acrivon Therapeutics or Clene?

Clene (CLNN) is larger, with a market capitalization of $50.69M compared with $49.35M for Acrivon Therapeutics (ACRV).

Which stock has performed better over the past year, ACRV or CLNN?

ACRV returned -50.00% over the past 12 months, compared with -62.03% for CLNN (price return, excluding dividends). Past performance does not predict future results.

Are Acrivon Therapeutics and Clene in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons